BidaskClub Upgrades Pieris Pharmaceuticals (PIRS) to “Strong-Buy”
BidaskClub upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a buy rating to a strong-buy rating in a research note published on Monday.
A number of other research analysts have also weighed in on the stock. HC Wainwright boosted their target price on shares of Pieris Pharmaceuticals from $9.00 to $12.00 and gave the stock a buy rating in a research report on Tuesday, January 16th. William Blair initiated coverage on shares of Pieris Pharmaceuticals in a research report on Wednesday, January 17th. They set an outperform rating for the company. Finally, ValuEngine lowered shares of Pieris Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, December 1st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $10.00.
Pieris Pharmaceuticals (NASDAQ:PIRS) opened at $7.15 on Monday. Pieris Pharmaceuticals has a 52-week low of $1.88 and a 52-week high of $8.58.
In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the business’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $7.35, for a total transaction of $12,565,707.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.05% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in PIRS. State Street Corp acquired a new position in Pieris Pharmaceuticals during the 2nd quarter worth $2,377,000. Northern Trust Corp acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at about $1,625,000. TIAA CREF Investment Management LLC acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at about $649,000. Vanguard Group Inc. acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at about $526,000. Finally, Strs Ohio raised its position in shares of Pieris Pharmaceuticals by 1,028.0% during the fourth quarter. Strs Ohio now owns 112,800 shares of the biotechnology company’s stock valued at $851,000 after buying an additional 102,800 shares during the last quarter. 50.78% of the stock is owned by hedge funds and other institutional investors.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.